Register a trial

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04396756




Registration number
NCT04396756
Ethics application status
Date submitted
6/05/2020
Date registered
21/05/2020

Titles & IDs
Public title
Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis
Scientific title
A Randomized, Double-blind, Dose-ranging, Placebo Controlled Phase 2a Evaluation of the Safety, Tolerability and Pharmacokinetics of PLN-74809 in Participants With Idiopathic Pulmonary Fibrosis (INTEGRIS-IPF)
Secondary ID [1] 0 0
INTEGRIS-IPF
Secondary ID [2] 0 0
PLN-74809-IPF-202
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Idiopathic Pulmonary Fibrosis 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Inflammatory and Immune System 0 0 0 0
Connective tissue diseases
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - PLN-74809
Treatment: Drugs - Placebo

Experimental: Placebo - Placebo

Experimental: PLN-74809 Dose Level 1 (Part A) - PLN-74809 Dose Level 1 (Part A) - 4 weeks

Experimental: PLN-74809 Dose Level 2 (Part A) - PLN-74809 Dose Level 2 (Part A) - 4 weeks

Experimental: PLN-74809 Dose Level 2 (Part B) - PLN-74809 Dose Level 2 (Part B) - 12 weeks

Experimental: PLN-74809 - Dose Level 3 (Part C) - PLN-74809 Dose Level 3 (Part C) - 12 weeks

Experimental: PLN-74809 - Dose Level 4 (Part C) - PLN-74809 Dose Level 4 (Part C) - 12 weeks

Experimental: PLN-74809 - Dose Level 5 (Part D) - PLN-74809 Dose Level 5 (Part D) - = 24 weeks


Treatment: Drugs: PLN-74809
PLN-74809

Treatment: Drugs: Placebo
Placebo
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Part A - Number of Participants With Treatment-Emergent Adverse Events
Timepoint [1] 0 0
Up to 4 weeks
Primary outcome [2] 0 0
Part B, C, D - Number of Participants With Treatment-Emergent Adverse Events
Timepoint [2] 0 0
Up to 12 weeks
Primary outcome [3] 0 0
Part D - Number of Participants With Treatment-Emergent Adverse Events
Timepoint [3] 0 0
Up to 48 weeks
Primary outcome [4] 0 0
Part A - Number of Participants With Serious Treatment-Emergent Adverse Events
Timepoint [4] 0 0
Up to 4 weeks
Primary outcome [5] 0 0
Part B, C, D - Number of Participants With Serious Treatment-Emergent Adverse Events
Timepoint [5] 0 0
Up to 12 weeks
Primary outcome [6] 0 0
Part D - Number of Participants With Serious Treatment-Emergent Adverse Events
Timepoint [6] 0 0
Up to 48 weeks
Secondary outcome [1] 0 0
Part A - Assessment of PLN-74809 Total Plasma Concentrations
Timepoint [1] 0 0
Week 4, 1 Hour Post Dose
Secondary outcome [2] 0 0
Part B, C, D - Assessment of PLN-74809 Total Plasma Concentrations
Timepoint [2] 0 0
Week 12, 2 Hours Post Dose
Secondary outcome [3] 0 0
Part D - Assessment of PLN-74809 Total Plasma Concentrations
Timepoint [3] 0 0
Week 24, 2 Hours Post Dose

Eligibility
Key inclusion criteria
* Diagnosis of IPF based upon the Fleischner Society guidelines within 3 years from Screening (Part A) or based on ATS/ERS/JRS/ALAT 2018 guidelines within 5 years from Screening (Part B, C & D)
* FVC % of predicted =45%
* DLco (hemoglobin-adjusted) =30%
* Participants receiving treatment for IPF with nintedanib or pirfenidone are allowed, if on a stable dose for at least 3 months
Minimum age
40 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Currently receiving or planning to initiate treatment for IPF (fibrosis) with agents not approved for that indication by the FDA
* Forced expiratory volume during the first seconds of the forced breath (FEV1)/FVC ratio <0.7 at Screening
* Clinical evidence of active infection, including but not limited to bronchitis, pneumonia, sinusitis that can affect FVC measurement or IPF progression
* Known acute IPF exacerbation or suspicion by the Investigator of such, within 6 months of Screening
* Smoking of any kind within 3 months of Screening

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
3/03/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
15/02/2023
Sample size
Target
Accrual to date
Final
120
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [2] 0 0
The Alfred Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
3004 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Massachusetts
Country [6] 0 0
United States of America
State/province [6] 0 0
Missouri
Country [7] 0 0
United States of America
State/province [7] 0 0
North Carolina
Country [8] 0 0
United States of America
State/province [8] 0 0
Pennsylvania
Country [9] 0 0
United States of America
State/province [9] 0 0
Tennessee
Country [10] 0 0
United States of America
State/province [10] 0 0
Texas
Country [11] 0 0
Belgium
State/province [11] 0 0
Leuven
Country [12] 0 0
Canada
State/province [12] 0 0
Ontario
Country [13] 0 0
Canada
State/province [13] 0 0
Quebec
Country [14] 0 0
Italy
State/province [14] 0 0
Milan
Country [15] 0 0
Netherlands
State/province [15] 0 0
EJ
Country [16] 0 0
Netherlands
State/province [16] 0 0
SZ
Country [17] 0 0
New Zealand
State/province [17] 0 0
Auckland
Country [18] 0 0
New Zealand
State/province [18] 0 0
Christchurch

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Pliant Therapeutics, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Pliant Therapeutics Medical Monitor
Address 0 0
Pliant Therapeutics, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results are available at https://clinicaltrials.gov/study/NCT04396756